VISIBLE aims to better understand experience of psoriasis for people of colour23 March 2022 | By European Pharmaceutical ReviewJanssen has announced plans to initiate a large-scale study into the impact of psoriasis among black, Hispanic, Asian, indigenous and other people of colour.
Intravacc publishes GMP vaccine candidate manufacturing process23 March 2022 | By Hannah Balfour (European Pharmaceutical Review)A new paper details the GMP manufacturing and formulation process for a semi-synthetic Shigella glycoconjugate vaccine candidate from Institut Pasteur.
Could ‘drug factory’ beads help combat cancer?23 March 2022 | By Hannah Balfour (European Pharmaceutical Review)New pre-clinical testing shows interleukin producing ‘drug factory’ implants can eliminate ovarian and colorectal cancer in mice.
Novasep announces €5.1mn investment to grow HPAPI production22 March 2022 | By Hannah Balfour (European Pharmaceutical Review)The €5.1 million will add a new chemical synthesis workshop for HPAPIs, expanding Novasep’s HPAPI production capacity at its Le Mans site in France.
New preventative medicine for COVID-19 authorised in UK22 March 2022 | By European Pharmaceutical ReviewThe UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has reported that Evusheld, developed by AstraZeneca, has been granted approval to help protect against the effects of COVID-19.
Terahertz light could enhance QC of chiral drugs22 March 2022 | By Hannah Balfour (European Pharmaceutical Review)A study shows terahertz light creates twisting vibrations in biomolecules, enabling the analysis of their compositions and structures.
Blood pressure tablets recalled due to high levels of nitrosamine22 March 2022 | By European Pharmaceutical ReviewPfizer is voluntarily recalling Accuretic tablets and two generic high blood pressure treatments, due to levels of nitrosamine above ADI.
Catalent invests $30 million to modernise biopharmaceuticals site22 March 2022 | By Hannah Balfour (European Pharmaceutical Review)The completed modernisation of Catalent’s facility in Limoges, France, will support the development of early phase and small-scale commercial biologic drugs.
Empagliflozin trial halted after successful outcome in chronic kidney disease21 March 2022 | By European Pharmaceutical ReviewAn early halt has been called to a major kidney drug trial following positive results for patients with chronic kidney disease (CKD).
Potential for a new one-and-done COVID-19 treatment18 March 2022 | By Mandy Parrett (European Pharmaceutical Review)Investigational drug Lambda reduced risk of COVID-19-related death in one of the largest studies of its kind to date.
Generic manufacturers to produce COVID-19 treatment nirmatrelvir18 March 2022 | By Hannah Balfour (European Pharmaceutical Review)Pfizer’s oral COVID-19 treatment nirmatrelvir will be produced by 35 generic manufacturers to increase supply for low- and middle-income countries.
Lynparza® significantly reduces risk of death in early breast cancer patients18 March 2022 | By Hannah Balfour (European Pharmaceutical Review)Lynparza® (olaparib) is the first PARP inhibitor to demonstrate overall survival benefit in early breast cancer, according to new data.
USP Medicine Supply Map to help improve pharma supply chain resilience17 March 2022 | By Hannah Balfour (European Pharmaceutical Review)Unveiling its Medicine Supply Map, the US Pharmacopeia (USP) showed how reliant the US pharma supply chain is on Indian API manufacturers.
Is Aduhelm® of benefit to Alzheimer’s patients long-term?17 March 2022 | By Hannah Balfour (European Pharmaceutical Review)New data shows that patients taking Aduhelm® (aducanumab-avwa) had significant reductions in tau and amyloid beta after nearly 2.5 years.
AbbVie’s preventative migraine treatment atogepant (Qulipta™) shows promise16 March 2022 | By Mandy Parrett (European Pharmaceutical Review)AbbVie releases promising results from its Phase III trial of atogepant (Qulipta™) for preventative treatment of chronic migraine.
![Catalent logo on website through a magnifying glass [Credit: Pavel Kapysh/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Catalent-300x278.jpg)
![Catalent logo on website through a magnifying glass [Credit: Pavel Kapysh/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Catalent-e1647945626125.jpg)
